| PD-1/PD-L1 targeting in breast cancer: the first clinical evidences are emerging—a literature review G Planes-Laine, P Rochigneux, F Bertucci, AS Chrétien, P Viens, ... Cancers 11 (7), 1033, 2019 | 216 | 2019 |
| Prognostic significance of circulating PD-1, PD-L1, pan-BTN3As, BTN3A1 and BTLA in patients with pancreatic adenocarcinoma B Bian, D Fanale, N Dusetti, J Roque, S Pastor, AS Chretien, L Incorvaia, ... Oncoimmunology 8 (4), e1561120, 2019 | 115 | 2019 |
| Cancer-induced alterations of NK-mediated target recognition: current and investigational pharmacological strategies aiming at restoring NK-mediated anti-tumor activity AS Chretien, A Le Roy, N Vey, T Prebet, D Blaise, C Fauriat, D Olive Frontiers in immunology 5, 122, 2014 | 89 | 2014 |
| PTEN expression controls cellular response to cetuximab by mediating PI3K/AKT and RAS/RAF/MAPK downstream signaling in KRAS wild-type, hormone refractory prostate cancer cells S Bouali, AS Chrétien, C Ramacci, M Rouyer, P Becuwe, JL Merlin Oncology reports 21 (3), 731-735, 2009 | 83 | 2009 |
| Natural killer defective maturation is associated with adverse clinical outcome in patients with acute myeloid leukemia AS Chretien, C Fauriat, F Orlanducci, C Galseran, J Rey, G Bouvier Borg, ... Frontiers in immunology 8, 573, 2017 | 64 | 2017 |
| Endowing universal CAR T-cell with immune-evasive properties using TALEN-gene editing S Jo, S Das, A Williams, AS Chretien, T Pagliardini, A Le Roy, ... Nature Communications 13 (1), 3453, 2022 | 61 | 2022 |
| BTN3A is a prognosis marker and a promising target for Vγ9Vδ2 T cells based-immunotherapy in pancreatic ductal adenocarcinoma (PDAC) A Benyamine, C Loncle, E Foucher, JL Blazquez, C Castanier, ... Oncoimmunology 7 (1), e1372080, 2018 | 45 | 2018 |
| NKp46 expression on NK cells as a prognostic and predictive biomarker for response to allo-SCT in patients with AML AS Chretien, R Devillier, C Fauriat, F Orlanducci, S Harbi, A Le Roy, J Rey, ... Oncoimmunology 6 (12), e1307491, 2017 | 45 | 2017 |
| Endometrial carcinoma: Immune microenvironment and emerging treatments in immuno-oncology S Rousset-Rouviere, P Rochigneux, AS Chretien, S Fattori, L Gorvel, ... Biomedicines 9 (6), 632, 2021 | 43 | 2021 |
| NKp30 expression is a prognostic immune biomarker for stratification of patients with intermediate-risk acute myeloid leukemia AS Chretien, C Fauriat, F Orlanducci, J Rey, GB Borg, E Gautherot, ... Oncotarget 8 (30), 49548, 2017 | 41 | 2017 |
| Dynamic of systemic immunity and its impact on tumor recurrence after radiofrequency ablation of hepatocellular carcinoma P Rochigneux, JC Nault, F Mallet, AS Chretien, N Barget, AJ Garcia, ... Oncoimmunology, 2019 | 39 | 2019 |
| Underground adaptation to a hostile environment: acute myeloid leukemia vs. natural killer cells N Dulphy, AS Chrétien, Z Khaznadar, C Fauriat, A Nanbakhsh, ... Frontiers in immunology 7, 183214, 2016 | 37 | 2016 |
| P53 and PTEN expression contribute to the inhibition of EGFR downstream signaling pathway by cetuximab S Bouali, AS Chrétien, C Ramacci, M Rouyer, S Marchal, T Galenne, ... Cancer gene therapy 16 (6), 498-507, 2009 | 37 | 2009 |
| High-dimensional mass cytometry analysis of NK cell alterations in AML identifies a subgroup with adverse clinical outcome AS Chretien, R Devillier, S Granjeaud, C Cordier, C Demerle, N Salem, ... Proceedings of the National Academy of Sciences 118 (22), e2020459118, 2021 | 34 | 2021 |
| Optimization of routine KRAS mutation PCR‐based testing procedure for rational individualized first‐line‐targeted therapy selection in metastatic colorectal cancer AS Chretien, A Harle, M Meyer‐Lefebvre, M Rouyer, M Husson, ... Cancer medicine 2 (1), 11-20, 2013 | 33 | 2013 |
| Mechanisms of NK cell dysfunction in the tumor microenvironment and current clinical approaches to harness NK cell potential for immunotherapy R Devillier, AS Chrétien, T Pagliardini, N Salem, D Blaise, D Olive Journal of Leucocyte Biology 109 (6), 1071-1088, 2021 | 32 | 2021 |
| Using one-step nucleic acid amplification (OSNA) for intraoperative detection of lymph node metastasis in breast cancer patients avoids second surgery and accelerates … S Klingler, F Marchal, P Rauch, O Kenouchi, AS Chrétien, P Genin, ... Annals of oncology 24 (9), 2305-2309, 2013 | 32 | 2013 |
| JAM-C identifies Src family kinase-activated leukemia-initiating cells and predicts poor prognosis in acute myeloid leukemia M De Grandis, F Bardin, C Fauriat, C Zemmour, A El-Kaoutari, A Sergé, ... Cancer research 77 (23), 6627-6640, 2017 | 28 | 2017 |
| Cellular response to cetuximab in PTEN-silenced head and neck squamous cell carcinoma cell line J Mriouah, C Boura, S Pinel, AS Chretien, A Fifre, JL Merlin, B Faivre International journal of oncology 37 (6), 1555-1563, 2010 | 28 | 2010 |
| Validation of a phosphoprotein array assay for characterization of human tyrosine kinase receptor downstream signaling in breast cancer F Chergui, AS Chretien, S Bouali, C Ramacci, M Rouyer, T Bastogne, ... Clinical chemistry 55 (7), 1327-1336, 2009 | 27 | 2009 |
